We have investigated the interaction between magnesium sulphate 40 mg kg" 1 i.v. and vecuronium. First, we determined the effect of pretreatment with magnesium on the potency of vecuronium using a single bolus dose-response technique. In addition, we compared the time course of vecuronium-induced neuromuscular block (vecuronium 100ugkg~1) with and without magnesium pretreatment. For both parts, neuromuscular block was assessed by electromyography. In addition, the effect of magnesium pretreatment on vecuronium-induced neuromuscular block was investigated in the context of rapid sequence induction of anaesthesia. We found that the neuromuscular potency of vecuronium was increased by pretreatment with magnesium sulphate. The ED 50 (9) min vs 25.2 (5.1) min for controls; P < 0.05). This was also true for the recovery index (20.1 (6.6) min vs 10.6 (3.4) min; P < 0.05) and duration to 75% recovery (63.4 (9.9) min vs 35.8 (6.9) min; P < 0.05). In the context of rapid sequence induction, pretreatment with MgSO 4 improved the intubating score of vecuronium compared with vecuronium without MgS0 4 , reaching the same quality as that with suxamethonium 1 mg kg" 1 . We conclude that magnesium pretreatment increased the neuromuscular potency of vecuronium, in addition to modifying the time course of its neuromuscular block. {Br. J. Anaesth. 1995; 74: 405-409) 
Magnesium sulphate (MgSO 4 ) has long been used in the treatment of pre-eclampsia and hypertension [1, 2] . In addition, MgSO 4 is increasingly used for haemodynamic control during anaesthesia [3, 4] . In a recent study it has been demonstrated that MgSO 4 as an adjuvant to general anaesthesia may modulate nociception, probably via its interaction with the NMDA receptor-associated calcium ionophore [5, 6] . Thus there are several situations in which the anaesthetist may be faced with a patient treated with MgSO 4 undergoing general anaesthesia. It is well known that MgSO 4 inhibits acetylcholine release at motor nerve terminals [7] ; consequently it may enhance the effect of neuromuscular blockers. Ghoneim and Long [1] found that MgSO 4 potentiated the neuromuscular block of depolarizing and non-depolarizing neuromuscular blockers, as was reported by Giesecke and colleagues [8] . Sinatra and colleagues [9] reported on a pre-eclamptic patient in whom the duration of vecuronium-induced neuromuscular block was prolonged markedly after pretreatment with MgSO 4 . Similar results have been reported by Skaredoff, Roaf andDatta [10] . However the interaction of MgSO 4 and vecuronium bromide has not been systematically investigated so far.
The aims of the present study were to establish a dose-response relationship for vecuronium in patients with and without MgSO 4 pretreatment, and to study the time course of vecuronium-induced neuromuscular block with and without MgSO 4 . In addition, we wished to see if pretreatment with MgSO 4 improved intubating conditions in a clinically relevant way when using vecuronium for rapid sequence induction.
Patients and methods
After obtaining institutional Ethics Committee approval and written informed consent, we studied 125 patients, ASA I or II, undergoing elective surgery. Patients were excluded if they were known to have neuromuscular disease or were receiving medications known to influence neuromuscular function. All patients were premedicated with midazolam 7.5 mg orally 1 h before arrival in the operating room.
In the first part of the study, 60 patients were allocated randomly to two groups of 30 patients each (groups A and B) for the study of dose-response In the second part of the study, another 20 patients were allocated randomly to group C (n = 10) or D (n = 10) to study the influence of pretreatment with MgSO 4 on the time constants of vecuronium-induced neuromuscular block. Patients in group C received MgSO 4 in a manner identical to the first part of the study, while patients in group D received saline alone. Anaesthesia was induced with fentanyl 2 ug kg" 1 and thiopentone 5 mg kg" 1 , and maintained with 1 % isofiurane, and 60 % nitrous oxide in oxygen via a face mask. When the end-tidal isoflurane concentration had stabilized, the Relaxograph was recalibrated and the control twitch height determined. Patients in both groups then received vecuronium lOOugkg" 1 as an i.v. bolus and the following intervals were measured: onset time = time between administration of vecuronium and maximum twitch depression; clinical duration (CD) = time between administration of vecuronium and recovery to 25% twitch height; recovery index (RI) = time from 25 % to 75 % twitch height recovery; and duration 75 = time between administration of vecuronium and recovery to 75 % twitch height.
End-tidal carbon dioxide concentration, body temperature and isoflurane concentrations were maintained stable during the whole study (4.5-5 vol%, 36.0-36.5 °C, 0.8-1 %, respectively). Patients did not receive further neuromuscular blockers until recovery to 100%+ 5% twitch height. Patients in whom twitch height did not recover to control levels were excluded from the study. For group C and D patients, we also determined the plasma concentrations of magnesium before and 15 min after the end of the MgSO 4 or placebo infusion.
In the third part of the study we assessed the quality of neuromuscular block in the context of rapid sequence induction. Anaesthesia was induced with alfentanil 10 ug kg" Forty-five patients were allocated randomly to one of three neuromuscular block techniques (n = 15 per group). The first group was pretreated with MgSO 4 40 mg kg" 1 in 100 ml of saline 15 min before rapid sequence induction and neuromuscular block with vecuronium 100 ug kg" 1 . The second group received 100 ml of saline as placebo pretreatment, again 15 min before rapid sequence induction and neuromuscular block with vecuronium lOOugkg" 1 . The third group received suxamethonium 1 mg kg" 1 for neuromuscular block 15 min after 100 ml of saline placebo. Sixty seconds after induction the trachea was intubated in all patients by the same experienced anaesthetist blinded to the treatment ( fig. 1) . He assessed the intubating conditions in each patient using the following criteria [11] : excellent = jaw relaxed, vocal cords abducted and immobile, and no (13) diaphragmatic movement; good = jaw relaxed, vocal cords abduced and immobile, but some diaphragmatic movement; poor = jaw relaxed, vocal cords moving, and coughing; and inadequate = jaw not relaxed and vocal cords closed.
Vecuronium dose-effect relationships for groups A and B were determined using linear regression analysis after log transformation of the doses and logit transformation of the twitch responses (log dose vs logit effect). To compare the neuromuscular potency of vecuronium with or without pretreatment with MgSO 4 the values of ED 50 and ED 90 were calculated for each group from the regression slopes. The regression slopes were tested for parallelism by analysis of covariance. The ED 50 and ED 90 values between the two groups were compared using an unpaired t test. For statistical comparison of the time constants of vecuronium-induced neuromuscular block in patients pretreated or not pretreated with MgSO 4 , the Mann-Whitney U test was used. Intubating conditions were analysed using the Kruskall-Wallis test after assigning a numeric value to each intubation score.
All values apart from intubating condition scores are expressed as mean (SD) or 95 % confidence limits. For statistical comparisons, differences were considered significant when P < 0.05.
Results
The study groups did not differ in age, sex distribution or weight (table 1) .
DOSE-RESPONSE STUDY
The regression lines of the dose-response curves did not deviate significantly from parallelism ( fig. 2) litre" 1 after the infusion (ns), respectively. The plasma magnesium concentrations after the MgSO 4 infusion were higher than after the placebo infusion (P < 0.05). The magnesium infusions were well tolerated, with no signs of muscular weakness. The only discomfort described by patients was a hot flush of the lower abdomen reported by 21 of the 55 patients.
INTUBATING CONDITIONS
Intubating conditions after pretreatment with MgSO 4 were significantly better than those obtained with vecuronium alone, and did not differ from those obtained with suxamethonium (table 5) .
Discussion
We have shown that the neuromuscular potency of vecuronium was increased markedly by MgSO 4 , the respective ED 50 and ED 90 values were 20-25 % lower in the magnesium group. For vecuronium without MgSO 4 , we found an ED 50 of 26.9 ug kg" 1 and an ED 90 of 45.7 ug kg" 1 . These data are in accordance with the results of other studies in which the single bolus technique has been used [12, 13] .
In order to quantify this interaction we used the single bolus dose-response technique instead of the cumulative technique described for long-acting neuromuscular blockers [14] . The latter technique may not be appropriate for vecuronium, as larger potency estimates are obtained by this method than with the single bolus technique [15] . This may arise because the effect of the initial dose of vecuronium has terminated before the last dose is given. For constructing the dose-response curves we used lower doses of vecuronium in patients pretreated with MgSO 4 . This was necessary because in the pilot dose-finding study we found that doses of vecuronium as high as 45 ug kg" 1 resulted in 100 % block of neuromuscular transmission after pretreatment with MgSO 4 . This would not have permitted correct construction of a dose-response relationship. We administered relatively low doses of MgSO 4 (i.e. 40 mg kg" 1 ). We chose this dose as it is currently used in our institution for obstetric patients. Even such small doses of MgSO 4 markedly increased the neuromuscular potency of vecuronium. This may be explained on the basis that the plasma concentration of magnesium was higher 15 min after MgSO 4 infusion than before, and higher than in controls. Non-depolarizing neuromuscular blockers have both presynaptic and postsynaptic activity at the neuromuscular junction [16] . Presynaptic action is thought to occur at nicotinic receptors on the nerve terminals that mediate autofacilitation of acetylcholine release, while the postsynaptic action inhibits end-plate depolarization [17] . MgSO 4 has mainly presynaptic effects by inhibiting acetylcholine release at motor nerve terminals [7] , effects which may be responsible for the interaction with vecuronium.
In the second part of the study we examined the influence of MgSO 4 on the time course of the neuromuscular block. We used the so-called "intubating dose" of vecuronium (i.e. 100 ug kg" 1 )-With this dose we found a clinical duration of action of about 25 min. However, after pretreatment with MgSO 4 the duration of vecuronium block was nearly doubled. The rapid recovery of neuromuscular function after vecuronium contributes to its safety in clinical practice. MgSO 4 decreases the recovery rate of vecuronium and considerably prolongs the time to achieve safe extubation conditions. A longer clinical duration of action together with slower recovery after an intubating dose of vecuronium when used together with magnesium results in a change in the total duration of vecuronium-induced curarization. In this context vecuronium no longer has the profile of an intermediate-acting neuromuscular blocker.
The speed of onset of neuromuscular block for vecuronium was increased markedly in the MgSO 4 group; about 2 min compared with 5 min in the controls. This is in accordance with the study of Lampl and Dandoy [18] , where the speed of onset of atracurium was increased markedly when patients were pretreated with MgSO 4 . James, Schenk and Van Der Veen reported similar results for pancuronium [19] ; an onset time of 68.3 s after MgSO 4 pretreatment. The shorter onset time of vecuronium after MgSO 4 pretreatment may be a clinically interesting phenomenon, because it may contribute to improvement in intubating conditions.
To test this hypothesis, we determined the intubating scores for rapid sequence induction with vecuronium 100 ug kg" 1 with and without MgSO 4 pretreatment and compared them with those obtained after suxamethonium, the gold standard for rapid sequence induction. The intubating scores for the group receiving vecuronium and MgSO 4 pretreatment at 60 s after the rapid sequence induction were better than in those receiving vecuronium alone, and similar to the scores obtained after suxamethonium.
When using vecuronium 100 ug kg" 1 without MgSO 4 , intubation after 60 s was not ideal, but always possible. This may be explained by the findings of Donati, Meistelman and Plaud [20] that the onset of neuromuscular block after vecuronium is faster for the larynx than for peripheral muscles.
The increase in plasma concentration of magnesium in patients pretreated with MgSO 4 was statistically significant, but clinically safe as no symptoms of muscle weakness were reported by the patients. This is in accordance with the results of Baraka and Yazigi [21] who found no clinical or electromyographic signs of muscle weakness even at slightly higher plasma magnesium concentrations (1.7-2.5 mmol litre" 1 )-These data indicate that pretreatment with MgSO 4 40 mg kg" 1 does not induce any degree of measurable neuromuscular block when administered before the non-depolarizing blocker. Thus pretreatment with MgSO 4 40 mg kg" 1 is safe. MgSO 4 before vecuronium improves the intubating conditions of vecuronium for rapid sequence induction, and thus may be a useful clinical alternative for rapid sequence induction in some patients in whom the use of suxamethonium is contraindicated or controversial.
We conclude that MgSO 4 , administered before vecuronium, accelerated the onset of neuromuscular block necessary for intubation of the trachea, that MgSO 4 in the presence of vecuronium intensified and prolonged neuromuscular block, and that monitoring of neuromuscular function and reduction in dose of vecuronium are required when using these two drugs in combination.
